pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-2-180-185pulmo-698Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESМаркеры активности экзогенных интерстициальных заболеваний легкихExtrinsic interstitial lung disease activity markersОрловаГ. П.OrlovaG. P.

д. м. н., ведущий научный сотрудник Научно-исследовательского института интерстициальных и орфанных заболеваний легких Научно-клинического исследовательского центра ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России; тел.: (812) 499-68-02

MD, Chief Scientist, Research Institute of interstitial and orphan lung diseases, Research Clinical Center, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 499-68-02;

galorlova@mail.ruСурковаЕ. А.SurkovaE. A.

к. б. н., старший научный сотрудник лаборатории диагностики аутоиммунных заболеваний Научно-методического центра молекулярной медицины ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России; тел.: (812) 338-71-94

PhD in Biology, Senior Researcher at Laboratory of Diagnosis of Autoimmune Diseases, Research Center of Molecular Medicine, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 338-71-94;

easurkova@mail.ruЛапинС. В.LapinS. V.

к. м. н., заведующий лабораторией диагностики аутоиммунных заболеваний Научно-методического центра молекулярной медицины ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России; тел.: (812) 338-71-94;

PhD, Head of Laboratory of Diagnosis of Autoimmune Diseases, Research Center of Molecular Medicine, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 338-71-94;

svlapin@mail.ruГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России: 197022, Санкт-Петербург, ул. Льва Толстого, 6–8РоссияAcademician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; 6 – 8, L'va Tolstogo str., Saint-Petersburg, 197022, RussiaRussian Federation201624062016262180185Copyright © Орлова Г.П., Суркова Е.А., Лапин С.В., 20162016Орлова Г.П., Суркова Е.А., Лапин С.В.Orlova G.P., Surkova E.A., Lapin S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/698

Уровень гликопротеина Krebs von den Lungen-6 (KL-6), альвеоломуцина и белка булавчатых клеток (club cells) – СС16 при экзогенных интерстициальных заболеваниях легких был исследован методом иммуноферментного анализа. Обследованы больные пневмокониозом (n = 13), экзогенным аллергическим (n = 26) и экзогенным токсическим (n = 20) альвеолитом в период активности и ремиссии заболевания. Установлено, что KL-6 и альвеоломуцин являются более информативными маркерами для оценки активности экзогенных фиброзирующих альвеолитов по сравнению с СС16. Альвеоломуцин обладает более высокой специфичностью, но меньшей чувствительностью, чем KL-6, и может применяться для скринингового исследования при подозрении на экзогенные альвеолиты. Для оценки эффективности терапии экзогенных аллергических и токсических альвеолитов целесообразно мониторировать уровень KL-6 и альвеоломуцина сыворотки крови.

The aim of this study was to investigate values of pulmonary fibrosis markers alveomucin and KL-16 and the airway damage marker CC-16 for evaluating activity and progressing of extrinsic interstitial lung diseases (ILD) in dependence on etiology. Methods. Levels of Krebs von den Lungen-6 glycoprotein (KL-6), alveomucin and Clara cell protein (CC16) were measured using the ELISA method. The study involved 13 patients with pneumoconiosis, 26 patients with extrinsic allergic alveolitis (EAA) and 20 patients with extrinsic toxic alveolitis (ETA) both in active and stable status. Results. KL-6 and alveomucin were found to be more valuable markers for assessing activity of extrinsic fibrosing alveolitis compared to CC16. Alveomucin had higher specificity but lower sensitivity compared to KL-6. Conclusion. Alveomucin could be used as a screening test in cases with clinical susceptibility for extrinsic alveolitis. On contrary, KL-6 and alveomucin could be used for assessing therapeutic efficacy of EAA and ETA.

биомаркерыэкзогенный аллергический альвеолитэкзогенный токсический альвеолитпневмокониозактивность заболеванияbiomarkersextrinsic allergic alveolitisextrinsic toxic alveolitispneumoconiosisdisease activityReferencesИлькович М.М. Терминология и классификация. В кн.: М.М. Илькович, ред. Диссеминированные заболевания легких. М.: ГЭОТАР-Медиа; 2011: 10–13.Il'kovich M.M. Terminology and .characterization. In: M.M.Il'kovich, ed. Disseminated lung diseases. Moscow: GEOTAR-Media; 2011: 10–13 (in Russian).Kinnula V.L., Ishikawa N., Bergmann U. et al. Proteomic approaches for studying human parenchymal lung diseases. Exp. Rev. Proteomics. 2009; l (6): 619–629.Kinnula V.L., Ishikawa N., Bergmann U. et al. Proteomic approaches for studying human parenchymal lung diseases. Exp. Rev. Proteomics. 2009; l (6): 619–629.Nukiwa T. The role of biomarkers in management of interstitial lung disease: implication of biomarkers derived from type II pneumocytes. In: Du Bois R.M., Richeldi L., eds. Interstitial Lung Disease. Eur. Respir. Mon. UK.: ERS Journals Ltd; 2009, 46: 47–66.Nukiwa T. The role of biomarkers in management of interstitial lung disease: implication of biomarkers derived from type II pneumocytes. In: Du Bois R.M., Richeldi L., eds. Interstitial Lung Disease. Eur. Respir. Mon. UK.: ERS Journals Ltd; 2009, 46: 47–66.Hesselstrand R., Wildt M., Bozovic G. et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir. Med. 2013; 107 (7): 1079–1086.Hesselstrand R., Wildt M., Bozovic G. et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir. Med. 2013; 107 (7): 1079–1086.Xu L., Yan D.R., Zhu S.L. et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur. Rev. Med. Pharmacol. Sci. 2013; 17 (22): 3073–3077.Xu L., Yan D.R., Zhu S.L. et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur. Rev. Med. Pharmacol. Sci. 2013; 17 (22): 3073–3077.Fazlyeva R.M., Mavziutova G.A., Kuzovkina O.Z. Clinical and diagnostic value of the determination of alveomucin in patients with community-acquired pneumonia. Klin. Lab. Diagn. 2010; 3: 51–53.Fazlyeva R.M., Mavziutova G.A., Kuzovkina O.Z. Clinical and diagnostic value of the determination of alveomucin in patients with community-acquired pneumonia. Klin. Lab. Diagn. 2010; 3: 51–53.Zheng D., Limmon G.V., Yin L. et al. A cellular pathway involved in Clara cell to alveolar type II cell differentiation after severe lung injury. PLoS One 2013; 8 (8): e71028.Zheng D., Limmon G.V., Yin L. et al. A cellular pathway involved in Clara cell to alveolar type II cell differentiation after severe lung injury. PLoS One 2013; 8 (8): e71028.HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Kropski%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19188556"Kropski J., HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Fremont%20RD%5BAuthor%5D&cauthor=true&cauthor_uid=19188556"Fremont R., HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Calfee%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=19188556" Calfee C., HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Ware%20LB%5BAuthor%5D&cauthor=true&cauthor_uid=19188556"Ware L. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19188556" o "Chest."Chest. 2009; 135 (6): 1440–1447.Kropski J., Fremont R., Calfee C., Ware L. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009; 135 (6): 1440–1447.Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Invest. 2012; 50 (1): 3–13.Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Invest. 2012; 50 (1): 3–13.Ichiyasu H., Ichikado K., Yamashita A. et al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in non- specific interstitial pneumonia. Respiration. 2012; 83: 190–197.Ichiyasu H., Ichikado K., Yamashita A. et al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in non- specific interstitial pneumonia. Respiration. 2012; 83: 190–197.HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Ley%20B%5BAuthor%5D&cauthor=true&cauthor_uid=25260757"Ley B., HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Brown%20KK%5BAuthor%5D&cauthor=true&cauthor_uid=25260757"Brown K., HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=Collard%20HR%5BAuthor%5D&cauthor=true&cauthor_uid=25260757"Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/25260757" o "American journal of physiology. Lung cellular and molecular physiology."Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307: L681–L691.Ley B., Brown K., Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. American journal of physiology. Lung cellular and molecular physiology."Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307: L681–L691.Takahashi T., Munakata M., Ohtsuka Y. et al. Serum KL-6 concentrations in dairy farmers. Chest. 2000; 118: 445–450.Takahashi T., Munakata M., Ohtsuka Y. et al. Serum KL-6 concentrations in dairy farmers. Chest. 2000; 118: 445–450.Ohnishi H., Miyamoto S., Kawase S. et al. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/25098177"Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm. Med. 2014; 7 (14): 129. DOI: 10.1186/1471-2466-14-129.Ohnishi H., Miyamoto S., Kawase S. et al. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm. Med. 2014; 7 (14): 129. DOI: 10.1186/1471-2466-14-129.Kawase S., Hattori N., Ishikawa N. et al. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced inter Bronchiolar Clara cells play a critical role in lung homoeostasis interstitial lung disease. Respir. Res. 2011; 12: 97. HYPERLINK "http://respiratory-research.com/content/12/1/97"http://respiratory-research.com/content/12/1/97Kawase S., Hattori N., Ishikawa N. et al. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced inter Bronchiolar Clara cells play a critical role in lung homoeostasis interstitial lung disease. Respir. Res. 2011; 12: 97. http://respiratory-research.com/content/12/1/97Ohnishi H., Yokoyama A., Yasuhara Y. et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003; 58: 872–875.Ohnishi H., Yokoyama A., Yasuhara Y. et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003; 58: 872–875.Doishita S., Inokuma S., Asashima H. et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern. Med. 2011; 50 (23): 2889–2892.Doishita S., Inokuma S., Asashima H. et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern. Med. 2011; 50 (23): 2889–2892.Petrek M.., Hermans C., Kolek V. et al. Clara cell protein (CC16) in serum and bronchoalveolar lavage fluid of subjects exposed to asbestos. Biomarkers. 2002; 7 (1): 58–67.Petrek M.., Hermans C., Kolek V. et al. Clara cell protein (CC16) in serum and bronchoalveolar lavage fluid of subjects exposed to asbestos. Biomarkers. 2002; 7 (1): 58–67.Wang S.X.., Liu P., Wei M.T. et al. Roles of serum Сlara cell protein 16 and surfactant protein-D in the early diagnosis and progression of silicosis. J. Occup. Environ. Med. 2007; 49 (8): 834–839.Wang S.X.., Liu P., Wei M.T. et al. Roles of serum Сlara cell protein 16 and surfactant protein-D in the early diagnosis and progression of silicosis. J. Occup. Environ. Med. 2007; 49 (8): 834–839.Hałatek T., Trzcinka-Ochocka M., Matczak W., Gruchała J. Serum Clara cell protein as an indicator of pulmonary impairment in occupational exposure at aluminum foundry. Int. J. Occup. Med. Environ. Health. 2006; 19 (4): 211–223.Hałatek T., Trzcinka-Ochocka M., Matczak W., Gruchała J. Serum Clara cell protein as an indicator of pulmonary impairment in occupational exposure at aluminum foundry. Int. J. Occup. Med. Environ. Health. 2006; 19 (4): 211–223.Quintar A.A., Leimgruber C., García L. et al. Restoration of the normal Clara cell phenotype after chronic allergic inflammation. Int. J. Exp. Pathol. 2013; 94 (6): 399–411.Quintar A.A., Leimgruber C., García L. et al. Restoration of the normal Clara cell phenotype after chronic allergic inflammation. Int. J. Exp. Pathol. 2013; 94 (6): 399–411.

The authors declare that there are no conflicts of interest present.